Therapy Detail

Therapy Name AMG 337
Therapy Description

AMG 337 inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AMG 337 MET Inhibitor 50 AMG 337 inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp esophageal cancer sensitive AMG 337 Clinical Study Actionable In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108). 26432108
MET amp hepatocellular carcinoma sensitive AMG 337 Preclinical - Pdx & cell culture Actionable In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749). 27196749
MET amp stomach cancer sensitive AMG 337 Preclinical - Cell line xenograft Actionable In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782). 27196782
KRAS G12A MET amp lung cancer resistant AMG 337 Preclinical - Cell culture Actionable In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782). 27196782
Unknown unknown Advanced Solid Tumor not applicable AMG 337 Phase I Actionable In a Phase I trial, AMG 337 demonstrated safety and preliminary efficacy in patients with a variety of advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr e13538)). detail...
KRAS G12D MET amp esophageal carcinoma resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108). 26432108
MET amp lung cancer sensitive AMG 337 Preclinical - Cell culture Actionable In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782). 27196782
MET amp esophagus adenocarcinoma sensitive AMG 337 Clinical Study Actionable In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108). 26432108
ERBB2 amp TP53 R158H gastric adenocarcinoma predicted - resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108). 26432108
MET amp Advanced Solid Tumor decreased response AMG 337 Clinical Study Actionable In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232). 25326232
ERBB2 amp MET amp gastric adenocarcinoma resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108). 26432108
Clinical Trial Phase Therapies Title Recruitment Status
NCT03147976 Phase II AMG 337 QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT03132155 Phase II AMG 337 QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma Recruiting
NCT01253707 Phase I AMG 337 A Study of AMG 337 in Subjects With Advanced Solid Tumors Completed
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated
NCT02344810 Phase Ib/II AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn